Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice

Cytokine

Volumn 20, Issue 6, 2002, Pages 304-311

  Katsume, Asao ^a   Saito, Hiroyuki ^a   Yamada, Yoshiki ^a   Yorozu, Keigo ^a   Ueda, Otoya ^a   Akamatsu, Ken Ichi ^a   Nishimoto, Norihiro ^b   Kishimoto, Tadamitsu ^b   Yoshizaki, Kazuyuki ^b   Ohsugi, Yoshiyuki ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Antibodies; Castleman's disease; IL 6 IL 6R; Transgenic mouse

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BLOOD DISEASE; CAUSE OF DEATH; CHEMICAL PARAMETERS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENE FUSION; KIDNEY FAILURE; LEUKOCYTOSIS; MALE; MOUSE; NONHUMAN; PLASMACYTOSIS; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROMOTER REGION; PROTEIN BLOOD LEVEL; THROMBOCYTOSIS; TRANSGENIC MOUSE;

MURINAE; MUS MUSCULUS;

EID: 0036915034     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2002.2012     Document Type: Article

References (35)

1. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Advances in Immunol. 54:1993;1-78.
2. Yoshizaki K., Matsuda T., Nishimoto N., Kuritani T., Taeho L., Aozasa K., Nakahata T., Kawai H., Tagoh H., Komori T., Kishimoto S., Hirano T., Kishimoto T. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 74:1989;1360-1367.
3. Brant S.J., Bodine D.M., Dunbar C.E., Nienhuis A.W. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 86:1990;592-599.
4. Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., Sato K., Shimizu M., Murashima A., Tsunasawa S., Sakiyama F., Kishimoto T. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 18:1988;1797-1801.
5. Houssiau F.A., Devogelaer J.P., Damme J.V., de Deuxchaicnes C.N., Snick J.V. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis. Arthritis Rheum. 31:1988;784-788.
6. Horii Y., Muraguchi A., Iwano M., Matsuda T., Hirayama T., Yamada H., Fujii Y., Dohi K., Ishikawa H., Ohmoto Y., Yoshizaki K., Hirano T., Kishimoto T. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol. 143:1989;3949-3955.
7. Ruef C., Budde K., Lacy J., Northemann W., Baumann M., Sterzel R.B., Coleman D.L. Interleukin 6 is an autocrine growth factor for mesangial cell. Kidney Int. 38:1990;249-257.
8. Van Damme J., Opdenakker G., Simpson R.J., Rubira M.R., Cayphas S., Vink A., Billiau A., Van Snick J. Identification of the human 26-kD protein, interferon b2, as a cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. J Exp Med. 165:1987;914-919.
9. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 332:1988;83-85.
10. Hack C.E., de Groot E.R., Felt-Bersma R.J., Nuijens J.H., Strack Van Schijndel R.J., Eerenberg-Belmer A.J., Thijs L.G., Aarden L.A. Increased plasma levels of interleukin-6 in sepsis. Blood. 74:1989;1704-1710.
11. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1 and fatal outcome. J Exp Med. 169:1989;333-338.
12. Black K., Garrett I.R., Mundy G.R. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology. 128:1991;2657-2659.
13. Strassmann G., Fong M., Kenney J.S., Jacob C.O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 89:1992;1681-1684.
14. Beck J.T., Hsu S.M., Wijdense J., Bataille R., Klein B., Vesole D., Hayden K., Jagannath S., Barlogie B. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 330:1994;602-605.
15. Wendling D., Racadot E., Wijenes J. Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J Rheumatol. 20:1993;259-262.
16. Nishimoto N., Sasai M., Shima Y., Nakagawa M., Matsumoto T., Shirai T., Kishimoto T., Yoshizaki K. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 95:2000;56-61.
17. Suematsu S., Matsuda T., Aozasa K., Akira S., Nakano N., Ohno S., Miyazaki J., Yamamura K., Hirano T., Kishimoto T. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA. 86:1989;7547-7551.
18. Katsume A., Miyai T., Suzuki H., Moriguchi Y., Kawara H., Tatsumi T., Suematsu S., Kishimoto T., Ohugi Y. Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice. Clin Immuno Immunopathol. 82:1997;117-124.
19. Tsujinaka T., Ebisui C., Fujita J., Kishibuchi M., Morimoto T., Ogawa A., Katsume A., Ohsugi Y., Kominami E., Monden M. Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. Biochem Biophys Res Commun. 207:1995;168-174.
20. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., Koishihara Y., Ohsugi Y., Kumaki K., Taga T., Kishimoto T., Suda T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA. 90:1993;11924-11928.
21. Matsuda T., Hirano T., Kishimoto T. Establishment of an interleukin 6 (IL6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL6 monoclonal antibodies. Eur J Immunol. 18:1988;951-956.
22. Tsujinaka T., Fujita J., Ebisui C., Yano M., Kominami E., Suzuki K., Tanaka K., Katsume A., Ohsugi Y., Shiozaki H., Monden M. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest. 97:1996;244-249.
23. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 368:1994;339-342.
24. Muraguchi A., Hirano T., Tang B., Matsuda T., Horii Y., Nakajima K., Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 167:1988;332-344.
25. Wong G.G., Witek-Giannotti J.S., Temple P.A., Kriz R., Ferenz C., Hewick R.M., Clark S.C., Ikebuchi K., Ogawa M. Stimulation of murine hemopoietic colony formation by human IL-6. J Immunol. 140:1988;3040-3044.
26. Ulich T.R., del Castillo J., Guo K. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood. 73:1989;108-110.
27. Caracciolo D., Clark S.C., Rovera G. Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSF. Blood. 73:1989;666-670.
28. Takatsuki F., Okano A., Suzuki C., Miyasaka Y., Hirano T., Kishimoto T., Ejima D., Akiyama Y. Interleukin 6 perfusion stimulates reconstitution of the immune, and hematopoietic systems after 5-fluorouracil treatment. Cancer Res. 50:1990;2885-2890.
29. Kitamura H., Kawata H., Takahashi F., Higuchi Y., Furuichi T., Ohkawa H. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. Am J Pathol. 147:1995;1682-1692.
30. Wendling F., Maraskovsky E., Debili N., Florindo C., Teepe M., Titeux M., Methia N., Breton-Gorius J., Cosman D., Vainchenker W. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 369:1994;571-574.
31. Kaushansky K., Lok S., Holly R.D., Broudy V.C., Lin N., Bailey M.C., Forsrom J.W., Buddle M.M., Oort P.J., Hagen F.S., Roth G.J., Papayannopoulou T., Foster D.C. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 369:1994;568-571.
32. de Sauvage F.J., Hass P.E., Spencer S.D., Malloy B.E., Gurney A.L., Spencer S.A., Darbonne W.C., Henzel W.J., Wong S.C., Kuang W., Oles K.J., Hultgren B., Solberg L.A., Goeddel D.V., Eaton D.L. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 369:1994;533-538.
33. Nomura H., Imazeki I., Oheda M., Kubota N., Tamura M., Ono M., Ueyama Y., Asano S. Purification and characterization of human granulocyte colony-stimulating factor (G-CSF). EMBO J. 5:1986;871-876.
34. Fujita J., Tsujinaka T., Yano M., Ebisui C., Saito H., Katsume A., Akamatsu K., Ohsugi Y., Shiozaki H., Monden M. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer. 68:1996;637-643.
35. Kowalski-Saunders P.W., Winwood P.J., Arthur M.J., Wright R. Reversible inhibition of albumin production by rat hepatocytes maintained on a laminin-rich gel (Engelbreth-Holm-Swarm) in response to secretory products of Kupffer cells and cytokines. Hepatology. 16:1992;733-741.